{
Ionis Pharmaceuticals, Inc.

Companies

}
001122334455554433221100
001122334455554433221100
Symbol IONS
Name Ionis Pharmaceuticals, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State CA
City Carlsbad
Zipcode 92010
Website http://www.ionispharma.com
Track all markets on TradingView

Ionis Pharmaceuticals maintains focus on Tryngolza launch amid mixed analyst ratings

UBS analyst Esther Rajavelu has maintained a Neutral rating on Ionis Pharmaceuticals with a price target of $45, as the stock trades near its 52-week low at $31.40. The company is focused on launching Tryngolza for familial chylomicronemia syndrome and has partnered with Sobi for commercialization outside the U.S. Despite a revenue decline of 10.5% to $705 million, Ionis has secured EU approval for WAINZUA and is advancing its investigational treatments, while management anticipates Phase 3 data for olezarsen in severe hypertriglyceridemia by late 2025.
Investing.com South Africa
SoBit USD Ionis Pharmaceuticals, Inc. CAN CHN SWE USA Esther Rajavelu Show more
Business & Industry, Market Report
09:11 28.03.2025

ubs maintains neutral rating on ionis pharmaceuticals with stable price target

UBS analyst Esther Rajavelu has maintained a Neutral rating on Ionis Pharmaceuticals with a price target of $45, as the stock trades near its 52-week low at $31.40. The company is focused on launching Tryngolza for familial chylomicronemia syndrome and has partnered with Sobi for marketing outside the US. Despite generating $705 million in sales, Ionis is unlikely to reach profitability this year, with ongoing studies expected to yield phase 3 data for severe hypertriglyceridemia in 2025.
Investing.com France
SoBit USD Ionis Pharmaceuticals, Inc. CAN CHN USA Esther Rajavelu Show more
Business & Industry, Market Report
15:36 27.03.2025

Ionis Pharmaceuticals Advances Neurology Pipeline with Promising Clinical Developments

Ionis Pharmaceuticals presented its neurology pipeline at UBS Virtual CNS Day, focusing on rare neurological diseases such as Alexander disease, Angelman syndrome, and Alzheimer's disease. The company reported an 84% growth in WAYNEUWA sales and is optimistic about upcoming clinical trial results, including a Phase 3 trial for Angelman syndrome and data for Alexander disease expected later this year. Future plans include collaborations for faster diagnoses and expanding treatment options for young patients.
Investing.com Deutsch
Ionis Pharmaceuticals, Inc. BIOGEN USA
Healthcare & Medicine, Transcript
13:10 18.03.2025

Ionis Pharmaceuticals Reports Narrower Loss Amid Revenue Decline in Q3 2024

Ionis Pharmaceuticals reported a narrower loss of 95 cents per share for Q3 2024, beating estimates, while total revenues reached $134 million, surpassing expectations but declining 7% year over year. Commercial revenues fell to $76 million, missing estimates, with Spinraza royalties down 15%. Adjusted operating costs decreased 4.2% year over year, although expenses rose due to increased SG&A costs for new product launches.
Yahoo Finance
United States Dollar BIOGEN Ionis Pharmaceuticals, Inc. AstraZeneca PLC GBR USA Show more
Healthcare, Market Report
17:31 06.12.2024

nobel prize awarded for protein design and drug developments advance

David Baker, Demis Hassabis, and John Jumper have won the Nobel Prize in Chemistry for their groundbreaking work in computational protein design and structure prediction, significantly advancing drug design capabilities. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran to treat a severe form of transthyretin amyloidosis, while Johnson & Johnson halts a bladder cancer trial for TAR-200. AstraZeneca invests in a preclinical cholesterol-lowering drug, and Astellas acquires rights to an experimental gene therapy for frontotemporal dementia.
BioPharma Dive
United States Dollar Eli Lilly and Company AviadoBio Alnylam Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. Amgen Inc. Astellas Pharma Inc. Pfizer Inc. BridgeBio Pharma, Inc. Novartis AG AstraZeneca PLC Johnson & Johnson USA SWE JPN BRA HKG John Jumper David Baker Jonathan Gardner Demis Hassabis Jim Wilson Show more
Healthcare, News Article
13:00 09.10.2024
Trending
Subcategory
Startups & Entrepreneurship Industry Trends Corporate News Private Equity Deals Retail and Consumer Goods Supply Chain Management Global Trade Developments CEO Changes Government Economic Policies Corporate Social Responsibility Industry Mergers & Acquisitions Workplace Trends Energy Sector Developments Venture Capital Investments Fintech Startups Finance Mergers & Acquisitions AI Innovations Market Analysis and Predictions Intellectual Property Laws Central Bank Actions
Countries:
IND USA CHN SAU ARE SGP JPN QAT EGY MYS IDN GBR KOR BRA HKG VNM TWN DEU FRA IRL
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. Salesforce, Inc. Garuda Aerospace Ltd. Huawei Technologies CO. Ltd. Bharti Airtel Ltd. XPeng Inc. Microsoft Corporation Venturewave Capital NO.1 Ltd. Semler Scientific, Inc. TENCENT Wipro Ltd OpenAI ERC USD Orange S.A. IDBI Bank Limited Standard Chartered Bank LENOVO GROUP
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Saudi Riyal Japanese Yen Malaysian Ringgit British Pound Sterling Mexican Peso Brazilian Real New Taiwan Dollar Bahraini Dinar Qatari Riyal Pakistani Rupee Kuwaiti Dinar Vietnamese Đồng South Korean Won Algerian Dinar
People:
Donald Trump Mark Zuckerberg Bisrat Degefa He Xiaopeng Abdel Fattah El-Sisi Anmol Singh Jaggi Puneet Singh Jaggi Sari Sabban David Watkins Simon Moon Anas Algahtani Matt Jones Ayman Hamdan Elon Musk Allen Law Xi Jinping Anwar Hussain Sultan Ibrahim ibni Sultan Iskandar Prashant Joshi Albinder Dhindsa

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.